OpenAI's CEO is reportedly raising funds for a brain implant startup that would directly compete with Elon Musk's Neuralink.

Microsoft (MSFT)-backed OpenAI's latest venture, Merge Labs, is looking to develop a novel gene therapy approach targeting brain cells. Read more here.

Sam Altman plans to support a brain computer interface startup to rival Neuralink, as OpenAI expands its AI and technology ...

The company, which has been referred to as Merge Labs, is looking at an approach involving gene therapy that would modify ...

The Trump administration has ended potential enforcement actions against dozens of tech firms and 165 corporations overall, ...

Introducing the first batch of 5 seasoned VCs judging Startup Battlefield 200 at TechCrunch Disrupt 2025 in October. Register ...

Over dinner, OpenAI CEO’s addressed criticism of GPT-5’s rollout, the AI bubble, brain-computer interfaces, buying Google ...

Researchers said the technology could one day help people who cannot speak communicate more easily.View on euronews ...

OpenAI's Sam Altman spoke frankly during an intimate dinner with reporters about the rocky debut of GPT-5 and the company’s ...

Investing.com -- OpenAI CEO Sam Altman revealed ambitious plans for the company’s future during a dinner with Verge reporters in San Francisco on Thursday, including potential trillion-dollar ...

Four people living with severe paralysis, caused by conditions including amyotrophic lateral sclerosis and brainstem stroke, took part in the trial. One participant could only respond ...

Stanford researchers decode silent thoughts into speech with 74% accuracy, enabling paralyzed patients to communicate through ...